178 related articles for article (PubMed ID: 36013073)
1. The New Challenge in Pediatric Liver Transplantation: Chronic Antibody-Mediated Rejection.
Uebayashi EY; Okajima H; Yamamoto M; Ogawa E; Okamoto T; Haga H; Hatano E
J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013073
[TBL] [Abstract][Full Text] [Related]
2. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.
Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T
Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054
[TBL] [Abstract][Full Text] [Related]
3. Morphological characterization of chronic antibody-mediated rejection in ABO-identical or ABO-compatible pediatric liver graft recipients.
Dao M; Habès D; Taupin JL; Mussini C; Redon MJ; Suberbielle C; Jacquemin E; Gonzales E; Guettier C
Liver Transpl; 2018 Jul; 24(7):897-907. PubMed ID: 29704327
[TBL] [Abstract][Full Text] [Related]
4. Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts.
Smith RN; Malik F; Goes N; Farris AB; Zorn E; Saidman S; Tolkoff-Rubin N; Puri S; Wong W
Transpl Immunol; 2012 Oct; 27(2-3):107-13. PubMed ID: 22960786
[TBL] [Abstract][Full Text] [Related]
5. Banff Human Organ Transplant Transcripts Correlate with Renal Allograft Pathology and Outcome: Importance of Capillaritis and Subpathologic Rejection.
Rosales IA; Mahowald GK; Tomaszewski K; Hotta K; Iwahara N; Otsuka T; Tsuji T; Takada Y; Acheampong E; Araujo-Medina M; Bruce A; Rios A; Cosimi AB; Elias N; Kawai T; Gilligan H; Safa K; Riella LV; Tolkoff-Rubin NE; Williams WW; Smith RN; Colvin RB
J Am Soc Nephrol; 2022 Dec; 33(12):2306-2319. PubMed ID: 36450597
[TBL] [Abstract][Full Text] [Related]
6. Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection.
Ali S; Ormsby A; Shah V; Segovia MC; Kantz KL; Skorupski S; Eisenbrey AB; Mahan M; Huang MA
Transpl Immunol; 2012 Jan; 26(1):62-9. PubMed ID: 21907804
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
[TBL] [Abstract][Full Text] [Related]
8. Chronic AMR in Liver Transplant: Validation of the 1-Year cAMR Score's Ability to Determine Long-term Outcome.
O'Leary JG; Smith C; Cai J; Hart B; Jennings LW; Everly M; Klintmalm GB; Demetris AJ
Transplantation; 2017 Sep; 101(9):2062-2070. PubMed ID: 28452922
[TBL] [Abstract][Full Text] [Related]
9. Antibody-mediated rejection: treatment alternatives and outcomes.
Singh N; Pirsch J; Samaniego M
Transplant Rev (Orlando); 2009 Jan; 23(1):34-46. PubMed ID: 19027615
[TBL] [Abstract][Full Text] [Related]
10. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy.
Saito K; Nakagawa Y; Suwa M; Kumagai N; Tanikawa T; Nishiyama T; Ueno M; Gejyo F; Nishi S; Takahashi K
Xenotransplantation; 2006 Mar; 13(2):111-7. PubMed ID: 16623803
[TBL] [Abstract][Full Text] [Related]
11. Current outcomes of chronic active antibody mediated rejection - A large single center retrospective review using the updated BANFF 2013 criteria.
Redfield RR; Ellis TM; Zhong W; Scalea JR; Zens TJ; Mandelbrot D; Muth BL; Panzer S; Samaniego M; Kaufman DB; Astor BC; Djamali A
Hum Immunol; 2016 Apr; 77(4):346-52. PubMed ID: 26867813
[TBL] [Abstract][Full Text] [Related]
12. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
13. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection.
Theruvath TP; Saidman SL; Mauiyyedi S; Delmonico FL; Williams WW; Tolkoff-Rubin N; Collins AB; Colvin RB; Cosimi AB; Pascual M
Transplantation; 2001 Jul; 72(1):77-83. PubMed ID: 11468538
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation.
Kim MG; Kim YJ; Kwon HY; Park HC; Koo TY; Jeong JC; Jeon HJ; Han M; Ahn C; Yang J
Nephrology (Carlton); 2013 Dec; 18(12):820-6. PubMed ID: 24033843
[TBL] [Abstract][Full Text] [Related]
15. Acute antibody-mediated rejection in ABO-compatible pediatric liver transplant recipients: case series and review of the literature.
Wozniak LJ; Naini BV; Hickey MJ; Bhattacharyya S; Reed EF; Busuttil RW; Farmer DG; Vargas JH; Venick RS; McDiarmid SV
Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27597379
[TBL] [Abstract][Full Text] [Related]
16. Outcome of desensitization in human leukocyte antigen- and ABO-incompatible living donor kidney transplantation: a single-center experience in more than 100 patients.
Al Meshari K; Pall A; Chaballout A; El Gamal H; Al Mana H; Humaidan H; Alzayer F; Al Talhi M
Transplant Proc; 2013 May; 45(4):1423-6. PubMed ID: 23726587
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
[TBL] [Abstract][Full Text] [Related]
18. The clinical and genomic significance of donor-specific antibody-positive/C4d-negative and donor-specific antibody-negative/C4d-negative transplant glomerulopathy.
Hayde N; Bao Y; Pullman J; Ye B; Calder RB; Chung M; Schwartz D; Lubetzky M; Ajaimy M; de Boccardo G; Akalin E
Clin J Am Soc Nephrol; 2013 Dec; 8(12):2141-8. PubMed ID: 24030736
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection.
Pearl MH; Nayak AB; Ettenger RB; Puliyanda D; Palma Diaz MF; Zhang Q; Reed EF; Tsai EW
Pediatr Nephrol; 2016 Aug; 31(8):1341-8. PubMed ID: 27048228
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Bortezomib as an Adjunctive Therapy for Refractory Chronic Active Antibody-Mediated Rejection in Kidney Transplant Patients: A Single-Center Experience.
Larpparisuth N; Skulratanasak P; Premasathian N; Vongwiwatana A
Transplant Proc; 2019 Dec; 51(10):3293-3296. PubMed ID: 31732214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
